Equity multiplier, or assets relative to shareholders' equity, comes in at 10.02 for Titan Pharmaceuticals Inc; that's greater than it is for 93.07% of US stocks.
Revenue growth over the past 12 months for Titan Pharmaceuticals Inc comes in at -38.43%, a number that bests merely 4.9% of the US stocks we're tracking.
Titan Pharmaceuticals Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -54.36%, greater than the shareholder yield of only 7.43% of stocks in our set.
Stocks that are quantitatively similar to TTNP, based on their financial statements, market capitalization, and price volatility, are EMAN, VJET, NEON, HTGM, and OPGN.
TTNP's SEC filings can be seen here. And to visit Titan Pharmaceuticals Inc's official web site, go to www.titanpharm.com.
Titan Pharmaceuticals, Inc., a specialty pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. The company was founded in 1992 and is based in South San Francisco, California.
By John Vandermosten, CFA NASDAQ:TTNP READ THE FULL TTNP RESEARCH REPORT Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) has been working hard to set up the ecosystem required for successful commercialization of Probuphine. The company has expanded its distribution network to cover the entire United States working in partnership with several well-known specialty pharmaceutical players and has improved
— Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) reported a loss of $0.08 per share in the fourth quarter of 2019, in line with Wall Street expectation. — Q4 revenue was flat at $1.2 million, vs. $920,000 expected. — As at December 31, 2019, Titan had cash and cash equivalents of approximately $5.2 million. — Launch of […]